Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
176 hedge funds and large institutions have $979M invested in Avadel Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 58 increasing their positions, 43 reducing their positions, and 25 closing their positions.
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
35% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 43
14% more funds holding
Funds holding: 155 → 176 (+21)
0.97% more ownership
Funds ownership: 76.58% → 77.55% (+0.97%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
27% less call options, than puts
Call options by funds: $35.8M | Put options by funds: $48.9M
28% less capital invested
Capital invested by funds: $1.36B → $979M (-$376M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$28.3M |
| 2 |
Millennium Management
New York
|
+$14.7M |
| 3 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$9.27M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$9.01M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$7.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$26.3M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$19.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$11M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$7.34M |
AVDL Hedge Fund Activity: Q3 2024 in Review
176 of the 6,970 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2024, worth a combined $979M — down 28% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new AVDL positions and 25 closed out — a net gain of 21 holders — while 58 added to existing stakes and 43 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $28.3M. The largest seller was Polar Capital Holdings, cutting an estimated $26.3M.
- 176 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2024, up from 155 in Q2 2024.
- Funds reported $979M of Avadel Pharmaceuticals stock for Q3 2024, down 28% quarter-over-quarter.
- 46 funds opened new Avadel Pharmaceuticals positions in Q3 2024 and 25 closed out, a net change of +21 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2024 was Goldman Sachs, an estimated $28.3M added.
- The largest Avadel Pharmaceuticals seller in Q3 2024 was Polar Capital Holdings, an estimated $26.3M sold.
Based on aggregated 13F filings for Q3 2024.